Initial combination therapy of ambrisentan and tadalafil in connective tissue disease-associated pulmonary arterial hypertension (CTD-PAH) in the modified intention-to-treat population of the AMBITION study: post hoc analysis

OBJECTIVES: To evaluate initial combination therapy with ambrisentan plus tadalafil (COMB) compared with monotherapy of either agent (MONO), and the utility of baseline characteristics and risk stratification in predicting outcomes, in patients with connective tissue disease-associated pulmonary art...

Descripción completa

Detalles Bibliográficos
Autores principales: Kuwana, Masataka, Blair, Christiana, Takahashi, Tomohiko, Langley, Jonathan, Coghlan, John G
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BMJ Publishing Group 2020
Materias:
Systemic Sclerosis
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7213337/
https://www.ncbi.nlm.nih.gov/pubmed/32161055
http://dx.doi.org/10.1136/annrheumdis-2019-216274

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7213337/
https://www.ncbi.nlm.nih.gov/pubmed/32161055
http://dx.doi.org/10.1136/annrheumdis-2019-216274

Ejemplares similares